Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BrUOG 401: Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
NCT04792502Phase 2Recruiting
- Sponsor
- Brown University
- Start
- Jul 2022
- Primary completion
- Aug 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of mosunetuzumab in follicular lymphoma (FL), marginal zone lymphoma (MZL), sponsored by Brown University. Started Jul 2022; status: recruiting.
02
Drugs
mosunetuzumab
03
Conditions
follicular lymphoma (FL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT04792502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04792502.